Stifel Nicolaus Issues Pessimistic Forecast for IDEXX Laboratories (NASDAQ:IDXX) Stock Price

IDEXX Laboratories (NASDAQ:IDXX) had its target price decreased by investment analysts at Stifel Nicolaus from $775.00 to $675.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 19.54% from the company’s current price.

A number of other equities research analysts have also issued reports on the company. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group decreased their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, Barclays dropped their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $772.22.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $564.66 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $44.85 billion, a price-to-earnings ratio of 43.20, a PEG ratio of 3.41 and a beta of 1.72. The firm’s fifty day simple moving average is $623.04 and its 200 day simple moving average is $660.23. IDEXX Laboratories has a twelve month low of $356.14 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts expect that IDEXX Laboratories will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the sale, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 45,957 shares of company stock valued at $29,862,109. Company insiders own 0.98% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors have recently made changes to their positions in IDXX. Empowered Funds LLC raised its holdings in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth $265,000. Global Retirement Partners LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $238,000. Elevation Point Wealth Partners LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $36,000. Finally, Norges Bank acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $221,955,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.